Oncolytic Seneca Valley Virus: past perspectives and future directions.
Oncolytic Seneca Valley Virus: past perspectives and future directions.
复制标题
DOI：
10.2147/ov.s96915
复制
发表时间：
2016
影响因子：
6.7
通讯作者：
Burke MJ
中科院分区：
文献类型：
--
作者：
Burke MJ
Seneca Valley病毒分离株001（SVV-001）是小核糖核酸病毒科的溶瘤RNA病毒。它也是新属Senecavirus中发现的第一个小核糖核酸病毒。SVV-001通过RNA中间体复制，绕过DNA阶段，并且不能整合到宿主基因组中。SVV-001最初是作为胎儿成视网膜细胞培养物中的污染物被发现的，此后被鉴定为针对神经内分泌来源的肿瘤的有效溶瘤病毒。SVV-001具有许多特征，使其成为一种有吸引力的溶瘤病毒，即它能够通过静脉给药靶向和穿透实体肿瘤，无法插入突变，并且是一种具有选择性嗜性的自我复制RNA病毒。癌细胞。SVV-001已在儿童和成人早期研究中进行了研究，报告了安全性和一些临床疗效，尽管主要是在成人肿瘤中。这篇综述总结了SVV-001的现有知识及其作为溶瘤病毒的未来。
Seneca Valley Virus isolate 001 (SVV-001) is an oncolytic RNA virus of the Picornaviridae family. It is also the first picornavirus discovered of the novel genus Senecavirus. SVV-001 replicates through an RNA intermediate, bypassing a DNA phase, and is unable to integrate into the host genome. SVV-001 was originally discovered as a contaminant in the cell culture of fetal retinoblasts and has since been identified as a potent oncolytic virus against tumors of neuroendocrine origin. SVV-001 has a number of features that make it an attractive oncolytic virus, namely, its ability to target and penetrate solid tumors via intravenous administration, inability for insertional mutagenesis, and being a self-replicating RNA virus with selective tropism for cancer cells. SVV-001 has been studied in both pediatric and adult early phase studies reporting safety and some clinical efficacy, albeit primarily in adult tumors. This review summarizes the current knowledge of SVV-001 and what its future as an oncolytic virus may hold.